In fiscal year 2011, the top 10 medical device companies invested a combined $20 billion in R&D, a billion-dollar boost from 2010.1 As evidenced by this impressive spend, innovation is increasingly being made a priority, despite a sluggish economy and more limited resources. Although their investments are taking many forms—via improving existing products, developing powerful new technologies, and acquiring companies—a cornerstone of each R&D program is the careful gathering and analysis of extraordinary amounts of data to ensure that commercial strategies are sound and will provide the desired return on investment.
Analytic techniques map the patient journey through the care continuum – from internal medicine to cardiologist to interventional cardiologist to cardiac surgeon.
Leveraging Data in the Device World
Delve Into the Data: Gain an Edge and Grow Sales
The New ROI: Return on Innovation
Alan G. Reicheg is chief commercial officer at Qforma (Princeton, NJ). He is a 21-year life sciences industry veteran and has held leadership positions in marketing and managed care. At Qforma, he oversees all aspects of commercial operations including partnership alliances. Al received his BA from Rutgers University and is a member of the Coalition for Healthcare Communication. He recently wrote "Transforming Business: The Silver Lining of the Sunshine Act" for MD+DI. Reach him at [email protected]